SBFM - Multiplikator P/S Sunshine Biopharma, Inc.
The lack of mass sales due to the laboratory status of developments restricts the reduction of unit costs for Sunshine Biopharma (SBFM). However, ownership of patents for antiviral and oncology drugs will ensure control over therapy costs in the future. High competition in the generics segment necessitates the protection of R&D. The company's normalized P/S reflects the dynamics of capitalization to revenue, where the 0.10 mark characterizes this parameter.
Rincian analitis perusahaan Sunshine Biopharma (SBFM)
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Rasio Kabeh Utang marang Dana Pribadi Sunshine Biopharma|SBFM - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal sunshinebiopharma.com|SBFM - Utang perusahaan|Rasio utang marang nilai buku Sunshine Biopharma|SBFM - Utang jangka dawa perusahaan|Utang jangka cendhak Sunshine Biopharma|Rasio jangkoan perantara sunshinebiopharma.com
- indikator pendapatan resik lan kelipatan nilai:
SBFM - Bathi resik|Bathi sing dikarepake Sunshine Biopharma|SBFM - Pangali P/E|Kapitalisasi marang proyeksi bathi Sunshine Biopharma Inc.|SBFM - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Sunshine Biopharma|SBFM - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan Sunshine Biopharma|SBFM - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan sunshinebiopharma.com|SBFM - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Sunshine Biopharma
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:Sunshine Biopharma Inc. (SBFM)
The combination of oncology drug development and generic sales allows Sunshine Biopharma (SBFM) to balance innovation with stable cash flow. An analysis of the company's P/S chart demonstrates the ratio of market capitalization to annual revenue, which helps investors determine the degree of business overvaluation and promptly identify any gap between the issuer's fundamental earnings and its current exchange value.
Perusahaan pesaing
Koefisien rega marang pendapatan beigene.com|Halozyme - Kapitalisasi marang pendapatan|Multiplikator P/S Revolution Medicines Inc RVMD|AAPG - Rasio rega marang pendapatan|CGON (CG Oncology Therapeutics) - Rasio kapitalisasi marang pendapatan|UroGen Pharma Ltd. (URGN) - Rasio rega marang pendapatan|BCAX - Koefisien rega marang pendapatan|PSNL (Personalis) - Multiplikator P/S|ERAS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DCTH|Koefisien rega marang pendapatan Y-mAbs Corp|Rasio rega marang pendapatan Aura Biosciences, Inc. AURA|CADL: Rasio kapitalisasi marang pendapatan|Accuray - Multiplikator P/S|Rega marang dodolan SELLAS Life Sciences|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Citius Oncology Inc - Rasio kapitalisasi pasar marang pendapatan|HURA (TuHURA Biosciences Inc.) - Multiplikator P/S|Rasio rega marang pendapatan TARA|Multiplikator P/S FATE|Koefisien rega marang pendapatan aadibio.com|Rasio rega marang pendapatan TScan Therapeutics, Inc. TCRX|Champions Oncology Inc (CSBR) - Rega marang dodolan|XBIT - Rasio rega marang pendapatan|Rasio rega marang dodolan CVM|OSTX: Multiplikator P/S|radiopharmtheranostics.com - Rasio kapitalisasi pasar marang pendapatan|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator P/S|Multiplikator P/S Adlai Nortye Limited|Rasio rega marang pendapatan Veru Inc. (VERU)|TPST (tempesttx.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Xilio Therapeutics XLO|RENB - Kapitalisasi marang pendapatan|Mural Bio - Multiplikator P/S|KAPA - Multiplikator P/S|onkuretherapeutics.com (OKUR) - Rasio rega marang pendapatan|GDTC - Koefisien rega marang pendapatan|CRIS (Curis Inc.) - Multiplikator P/S|Rasio rega marang pendapatan APLM|Multiplikator P/S THAR|ADVB: Rasio rega marang dodolan|Rasio rega marang pendapatan Genprex, Inc. GNPX|CLDI - Kapitalisasi marang pendapatan|Xenetic Bio - Multiplikator P/S|Salarius Pharmaceuticals Inc (SLRX) - Kapitalisasi marang pendapatan|PPBT: Multiplikator P/S|American Oncology Network, Inc. (AONC) - Multiplikator P/S|Rasio rega marang pendapatan BeiGene, Ltd.|Rasio kapitalisasi marang pendapatan CKPT (checkpointtx.com)|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan icadmed.com ICAD|Multiplikator P/S IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Rega marang dodolan|VIRX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Kapitalisasi marang pendapatan|Ascentage Pharma Group International - Rasio kapitalisasi pasar marang pendapatan
